Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis

R. Allendoerfer, D. Loebenberg, M. G. Rinaldi, J. R. Graybill

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


The efficacy of a novel triazole, SCH51048, was assessed with a murine model of pulmonary aspergillosis and was compared with those of SCH39304 and itraconazole. A wide range of doses of SCH51048 (5 to 50 mg/kg of body weight) was evaluated. Mortality was significantly delayed in mice treated with doses of 5 mg of SCH51048 per kg or greater in comparison with mortality in controls (P < 0.05). Both SCH51048 and SCH39304 at higher doses (30 and 50 mg/kg) reduced the number of viable Aspergillus fumigatus organisms in lung tissue (P < 0.05). In the present model, itraconazole neither delayed mortality nor significantly reduced the counts in tissue at the doses used. We conclude that SCH51048 is an effective therapy for murine pulmonary aspergillosis.

Original languageEnglish (US)
Pages (from-to)1345-1348
Number of pages4
JournalAntimicrobial agents and chemotherapy
Issue number6
StatePublished - 1995
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis'. Together they form a unique fingerprint.

Cite this